AGENDA
Programme will be added once finalised.
Check the program of the previous edition HERE
DAY 1
Thursday, 22 May 2025
8h15
Welcome coffee and registration
8h45
Welcome address
- Plenary
Chairman
10h00
Titre de la présentation
Prénom NOM
Fonction
Entreprise, Pays
9h15
Keynote lecture
- Plenary
Chairman
10h00
Organoids and stem cells for disease modeling and therapy
Ludovic Vallier
Professor of Stem Cells for Regenerative Therapies
Max Planck Institute - Germany
9h45
Track 1: Pioneering Research and Applications in iPS cells
- Plenary
Chairman
9h45
Translation of pluripotent stem cell-based liver cell therapy into the clinic from an industrial perspective
Tuan Huy Nguyen
Co-Founder, President, and Chief Science Officer
GoLiver Therapeutics - France
10h05
Opti-ox programming technology for the development of cell therapies
Lauren Broom
Head of Cell Therapy Innovation
bit.bio - UK
10h25
Established new immunodeficient large animal model for receiving human induced pluripotent stem cell-derived hematopoietic grafts.
Mathias Brunet-Manquat
PhD Student
Etablissement Français du Sang / Centre de Recherche de Saint Antoine - France
10h45
Coffee break - Exhibition Hall
11h15
Roundtable: Lessons Learned: Insights from Biotechs Post-Fundraising
- Plenary
Chairman
10h00
Titre de la présentation
Prénom NOM
Fonction
Entreprise, Pays
12h15
Lunch - Exhibition Hall - B2B Meetings
14h00
Keynote lecture
- Plenary
Chairman
14h00
Development and validation of an intravenous AAV gene therapy for mucopolysaccharidosis type IIIB in mouse and dog model of the pathology
Francoise Piguet
Head of the innovation unit GENOV
Institut du Cerveau - France
14h30
Track 2: Viral and Non-Viral Vectors : target optimization
- Plenary
Chairman
14h30
Advances in Gene Expression Optimization: AI-Driven Capsid Engineering for Targeted Therapeutics
Stephane Degove
CEO
Atamyo - France
14h50
Improving AAV Vectors efficacy and specificity via chemical conjugation
Lolita Petit
CSO
Coave Therapeutics - France
15h10
Development of targeted LNP
Catalina Bordeianu
Laboratory Head, Principal Scientist
Sanofi - France
15h10
Title to be confirmed
Ernst Wagner
Professor of Pharmaceutical Biotechnology
Ludwig-Maximilians-Universität (LMU) - Germany
Center of Nanoscience in Munich - Germany
16h20
Coffe Break - Exhibition Hall - B2B Meetings
17h00
Breakthrough innovation session
- Plenary
Chairman
14h30
Titre de la présentation
Stephane Degove
Fonction
Atamyo - France
18h30
End of day 1
DAY 2
Friday, 23 May 2025
8h30
Welcome coffee and registration
9h00
Keynote lecture
- Plenary
Chairman
10h00
Title to be announced
9h00
Title to be announced
Sebastian Amigorena
Team Leader
Institut Curie - France
9h30
Track 3: Exploring the Future of CARs & TILs - session 1
- Plenary
Chairman
9h30
Nonclinical development of in vivo CAR-T for autoimmune diseases
Franck Chanut
Head of Preclinical Safety R&D Project France
Sanofi - France
9h50
Titlle to be announced
Michael Saitakis
Director, Immunotherapy
Mnemo Therapeutics - France
10h40
Coffee break - Exhibition Hall
11h30
Track 3: Exploring the Future of CARs & TILs - session 2
- Plenary
Chairman
11h30
Title to be confirmed
Christian Jorgensen
Director
IRMB - Institute for Regenerative Medicine & Biotherapy - France
11h30
Title to be confirmed
Emma Gillanders
Project Manager - Cancer Survivorship Group
Institut Gustave Roussy - France
12h10
Lunch - Exhibition Hall - B2B Meetings
14h00
Keynote lecture
- Plenary
Chairman
10h00
Titre de la présentation
Francoise Piguet
Fonction
Institut du Cerveau - France
14h30
Track 4: Gene Editing: Innovations, Challenges, and Applications
- Plenary
Chairman
14h30
Title to be confirmed
Makoto Miyara
Professor
AP-HP, Assistance Publique - Hôpitaux de Paris - France
14h30
Title to be confirmed
Laurent Poirot
Senior Vice President, Immunology
Cellectis - France
15h40
